Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.68 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345238 | 0.93 | PDE10A (0.72) | PDE10ATLR7LMNA | |
| SCHEMBL19852576 | 0.92 | PDE10A (0.69) | PDE10ATLR7CYP3A4LMNA | |
| SCHEMBL15033553 | 0.88 | PDE10A (0.70) | PDE10ATLR7 | |
| SCHEMBL15033358 | 0.88 | PDE10A (0.64) | PDE10ATLR7CYP3A4 | |
| SCHEMBL12066512 | 0.86 | PDE10A (0.67) | PDE10ATLR7LMNA | |
| SCHEMBL12068175 | 0.86 | PDE10A (0.67) | PDE10ATLR7LMNA | |
| Hydrochloric Acid SCHEMBL15023818 | 0.85 | PDE10A (0.66) | PDE10ATLR7LMNA | |
| SCHEMBL15033361 | 0.85 | PDE10A (0.55) | PDE10ATLR7CYP3A4 | |
| SCHEMBL12066513 | 0.84 | PDE10A (0.71) | PDE10ATLR7 | |
| SCHEMBL15023389 | 0.83 | PDE10A (0.72) | PDE10ATLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885TLR7 4107/4885CYP3A4 191/4885 |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885TLR7 4107/4885CYP3A4 191/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885TLR7 4107/4885CYP3A4 191/4885 |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885TLR7 4107/4885CYP3A4 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.